Novel, Innovative Therapeutics

Dedicated to developing treatments to significantly improve and/or extend the life of patients.

Learn More

Customized Antibodies

Humaneered® antibodies designed based on sound scientific rationale for optimum activity in targeted patient populations

Learn More

Robust Monoclonal Antibody Pipeline

First-in-class, clinical stage programs with potential in multiple indications.

Learn More

Advancements in our Pipeline

Learn More

Our pipeline is comprised of first or best-in-class antibody therapeutic candidates for serious respiratory diseases and cancer.

Better Life Through Better Science

KaloBios is developing a robust proprietary portfolio of customized, targeted, first-in-class monoclonal antibodies designed to significantly improve the care of seriously ill patients with difficult to treat diseases.

Recent Corporate Highlights

  • Completed enrollment in 180 patient Phase 2 cystic fibrosis study for KB001-A
  • Initiated Phase 2 expansion portion of clinical trial for KB004 in hematologic malignancies
  • Announced preliminary Phase 1 results in advanced hematologic malignancies with KB004 at ASH Annual Meeting
  • KB001-A granted Fast Track Status in Pa pneumonia prevention
  • Received Orphan Drug designation from both the United States Food and Drug Administration (FDA) and the European Medicines Agency for KB001-A for the treatment of Pa lung infection in CF patients

Read All

Latest News

August 14, 2014

Publication by KaloBios and Collaborators Shows EphA3 as Target for Highly Selective Anticancer Therapy

August 7, 2014

KaloBios Provides Clinical Update and Reports Second Quarter Financial Results

July 28, 2014

KaloBios Provides Update on KB001-A Partnership and Clinical Status

May 8, 2014

KaloBios Provides First Quarter 2014 Financial Results
-- Provides Update on Clinical Programs and Timelines --

May 6, 2014

Ted W. Love, MD, Named Chairman of the Board of KaloBios

March 13, 2014

KaloBios Announces Fiscal Year 2013 Financial Results

You are now leaving this website. If you would like to continue, click Continue.